Vitamin D3
Vitamin D3 (cholecalciferol) is a fat-soluble secosteroid hormone precursor synthesized in skin upon UVB exposure and converted to the biologically active calcitriol (1,25-dihydroxyvitamin D) by sequential hepatic and renal hydroxylation. As a nuclear hormone with a receptor (VDR) expressed in virtually every tissue, calcitriol regulates over 1,000 genes spanning immune tolerance, bone metabolism, cardiovascular function, cancer suppression, and neuroprotection, making vitamin D deficiency one of the most consequential nutritional insufficiencies in modern populations.
Key Takeaways
- •A fat-soluble secosteroid synthesized in skin under UVB radiation, then hydroxylated in liver (to 25-OH-D3, the storage form measured clinically) and kidney (to 1,25-OH2-D3, calcitriol, the active hormone); supplementing with D3 (cholecalciferol) raises blood levels more effectively than D2 (ergocalciferol).
- •Calcitriol binds the Vitamin D Receptor (VDR), a nuclear transcription factor expressed in virtually every cell type, forming a heterodimer with RXR to regulate over 1,000 target genes involved in immune function, cell differentiation, calcium homeostasis, and inflammation.
- •Deficiency is epidemic: an estimated 1 billion people worldwide have insufficient 25-OH-D levels (below 30 ng/mL); risk is highest in individuals with limited sun exposure, darker skin, obesity, and older age due to impaired skin synthesis.
- •Clinical evidence supports vitamin D for bone health and fracture prevention, immune regulation (particularly reducing autoimmune risk and infection susceptibility), cardiovascular health, mental health, and cancer risk reduction, though RCT effect sizes in replete populations are often modest.
- •The CYP27B1 enzyme that converts 25-OH-D to active calcitriol is rate-limiting; genetic variants in CYP27B1 or in the VDR itself affect the functional dose-response and may require higher supplemental doses to achieve equivalent calcitriol tissue activity.
- •Optimal serum 25-OH-D for most health outcomes is 40 to 60 ng/mL (100 to 150 nmol/L); doses of 2,000 to 5,000 IU per day are typically needed to achieve this range in deficient individuals; toxicity from supplements requires sustained intake above 10,000 IU per day.
- •Always take with vitamin K2 at higher doses (above 4,000 IU/day) to support calcium routing to bone and reduce soft tissue calcification risk; magnesium is required as a cofactor for vitamin D metabolism and supplementation is often needed concurrently.
Basic Information
- Name
- Vitamin D3
- Also Known As
- CholecalciferolCalcitriol (active form)25-hydroxyvitamin D3 (storage form)Vitamin DSunshine vitamin
- Category
- Fat-soluble secosteroid / Nuclear hormone precursor
- Bioavailability
- D3 (cholecalciferol) absorbs well from supplements (up to 90%) when taken with fat-containing food; oil-based softgel capsules outperform dry powder tablets. D3 raises serum 25-OH-D approximately 87% more effectively than D2 (ergocalciferol) at equivalent doses. Obesity significantly reduces bioavailability due to sequestration in adipose tissue.
- Half-Life
- Plasma half-life of D3 itself is approximately 24 hours; the storage form 25-OH-D3 has a serum half-life of 2 to 3 weeks, which is why weekly or twice-weekly dosing is feasible. Active calcitriol has a very short half-life of 4 to 6 hours. Adipose tissue serves as a reservoir extending effective duration at adequate stores.
Quick Safety Summary
600 to 800 IU per day is the RDA for adults; 1,000 to 2,000 IU per day for general sufficiency maintenance; 4,000 to 5,000 IU per day to correct deficiency; up to 10,000 IU per day considered safe for most adults based on toxicological review. Toxicity threshold in healthy adults is generally above 10,000 IU per day sustained for months. Target serum 25-OH-D: 40 to 60 ng/mL (100 to 150 nmol/L).
Hypercalcemia or hypercalciuria: vitamin D supplementation is contraindicated as it will further increase calcium absorption and may worsen renal calcium deposition., Granulomatous diseases (sarcoidosis, tuberculosis, lymphoma): these conditions involve extrarenal conversion of 25-OH-D to calcitriol by activated macrophages; supplementation can cause severe hypercalcemia., Primary hyperparathyroidism: requires physician supervision as PTH-driven calcium dysregulation may be amplified., Stage 4 to 5 chronic kidney disease: impaired renal 1-alpha hydroxylase activity means D3 supplementation may be less effective; patients often require active calcitriol (alfacalcidol) under physician guidance.
Overview
Vitamin D3 (cholecalciferol) is a fat-soluble secosteroid that occupies a unique position in nutrition science as both a micronutrient and a steroid hormone precursor. It is synthesized in the skin upon UVB radiation (290 to 315 nm) acting on 7-dehydrocholesterol and undergoes two-step activation: first in the liver by CYP2R1 to produce 25-hydroxyvitamin D3 (calcidiol, the clinically measured storage form), then in the kidney by CYP27B1 to produce the biologically active 1,25-dihydroxyvitamin D3 (calcitriol). Industrial urbanization, indoor lifestyles, sun avoidance, widespread sunscreen use, and geographic latitude combine to make vitamin D deficiency among the most prevalent nutritional insufficiencies globally, with an estimated 1 billion people having levels below optimal health thresholds.
The biological activity of calcitriol is mediated almost entirely through its binding to the Vitamin D Receptor (VDR), a member of the nuclear receptor superfamily. The calcitriol-VDR complex heterodimerizes with the Retinoid X Receptor (RXR) and binds vitamin D response elements (VDREs) in the promoters of target genes. VDR is expressed in virtually every nucleated cell type, and systematic genome-wide analysis has identified over 1,000 genes regulated by VDR binding, spanning calcium metabolism, immune function, cell differentiation, DNA repair, and neuroprotection. This breadth of genomic influence explains why vitamin D status correlates epidemiologically with such a diverse range of health outcomes.
In immunology, calcitriol functions as a tolerogenic hormone. It promotes differentiation of monocytes toward a tolerogenic dendritic cell phenotype, induces FOXP3+ regulatory T-cell expansion, suppresses Th17 cell differentiation by reducing IL-17 and RORγt expression, and is a direct inducer of IL-10 production by regulatory T cells. Calcitriol also upregulates NOD2 and cathelicidin (CAMP) to enhance innate defense against intracellular pathogens while simultaneously dampening excessive inflammation. This dual role in supporting both antimicrobial defense and immune tolerance explains why deficiency is associated with both increased infection susceptibility and heightened autoimmune disease risk.
For supplementation strategy, D3 (cholecalciferol) raises serum 25-OH-D approximately 87% more effectively than D2 (ergocalciferol) at equivalent doses and is the preferred form. The conversion from D3 to active calcitriol depends on adequate substrate availability, CYP27B1 enzyme activity, and PTH-driven feedback regulation. Magnesium is an essential cofactor for every enzyme in the vitamin D activation pathway and is commonly deficient in populations supplementing vitamin D without concurrent magnesium. At doses above 4,000 IU per day, co-supplementation with vitamin K2 (MK-7) is advisable to support calcium routing to bone rather than soft tissues by activating osteocalcin and matrix Gla protein. Serum 25-OH-D testing at baseline and after 8 to 12 weeks of supplementation is the standard of care for dosage individualization.
Core Health Impacts
- • Immune regulation and tolerance: Calcitriol is a master regulator of immune tolerance, inducing FOXP3+ regulatory T-cell expansion, suppressing Th17 cell differentiation, upregulating IL-10 production, and downregulating NF-κB-mediated inflammatory cytokine expression. VDR is expressed on all immune cell types; deficiency is consistently associated with higher rates of autoimmune disease, infection susceptibility, and inflammatory conditions including multiple sclerosis, rheumatoid arthritis, and IBD.
- • Bone health and calcium metabolism: Calcitriol drives intestinal calcium absorption (by upregulating calbindin-D9k and TRPV6) and coordinates with PTH for renal calcium reabsorption and osteoclast-mediated bone resorption. Deficiency causes rickets in children and osteomalacia and accelerated osteoporosis in adults. Supplementation at adequate doses consistently reduces fracture risk in meta-analyses, particularly in elderly populations with baseline deficiency.
- • Cardiovascular protection: VDR activation represses the renin gene, reducing RAAS activity and supporting blood pressure control. Deficiency is associated with higher hypertension prevalence, endothelial dysfunction, and left ventricular hypertrophy. Calcitriol also supports vascular smooth muscle differentiation and reduces vascular calcification when vitamin K2 is co-administered. Epidemiological studies show strong inverse associations between 25-OH-D and cardiovascular disease mortality.
- • Cancer risk reduction: VDR signaling promotes cell differentiation, induces cell cycle arrest through CCND1 suppression and CDKN1A upregulation, upregulates E-cadherin to inhibit epithelial-to-mesenchymal transition, and physically sequesters beta-catenin from nuclear translocation. Meta-analyses support inverse associations between vitamin D status and colorectal, breast, and prostate cancer incidence and mortality. The VITAL trial showed a significant reduction in cancer mortality with supplementation in the overall cohort.
- • Mental health and neurological function: VDR is expressed in neurons, astrocytes, and microglia throughout the brain, and calcitriol upregulates neurotrophic factors (NGF, BDNF), modulates serotonin synthesis through TPH2 activation, and suppresses neuroinflammation. Deficiency is associated with higher rates of depression, cognitive decline, and dementia. Supplementation studies show modest benefits for depression and cognitive function, more consistently in deficient individuals.
- • Metabolic and insulin sensitivity: VDR is expressed in pancreatic beta cells and calcitriol supports insulin secretion by modulating intracellular calcium and upregulating insulin gene transcription. Deficiency is associated with impaired insulin secretion, insulin resistance, and higher type 2 diabetes incidence. VDR interactions with TCF7L2 and beta-catenin signaling provide additional links to pancreatic beta-cell function and glucose metabolism.
Gene Interactions
Key Gene Targets
AGTR1
Calcitriol downregulates the renin gene, reducing the total angiotensin II ligand pool available for AGTR1 activation; adequate vitamin D status is associated with lower blood pressure and reduced RAAS-driven cardiovascular risk.
APC
Promotes beta-catenin degradation through VDR-beta-catenin complex formation, reinforcing the tumor suppressor role of APC; adequate vitamin D is associated with lower colorectal adenoma risk and slower polyp progression.
CCND1
VDR signaling can antagonize the CCND1 promoter, reducing Cyclin D1 transcription and acting as a natural brake on hyper-proliferation; this anti-proliferative mechanism contributes to vitamin D's cancer-preventive activity.
CTLA4
Calcitriol is a master inducer of immune tolerance that upregulates CTLA4 on regulatory T cells, reinforcing the CTLA4-mediated co-inhibitory checkpoint that restrains excessive T-cell activation and autoimmunity.
CYP27B1
The essential hydroxylase enzyme that converts 25-OH-D3 to active calcitriol; vitamin D3 supplementation provides the raw material whose effectiveness depends critically on CYP27B1 enzyme speed, with genetic variants affecting conversion efficiency and functional response to supplementation.
FOXP3
Calcitriol is a potent direct inducer of FOXP3 expression in developing regulatory T cells; high vitamin D status supports Treg expansion and FOXP3-dependent immune tolerance, with clinical relevance to autoimmune disease prevention.
IL17A
An essential regulator of Th17/Treg balance; calcitriol suppresses RORγt and reduces IL-17A production, with low levels consistently associated with higher Th17 activity and autoimmune inflammation in rheumatoid arthritis, IBD, and multiple sclerosis.
SLC6A4
Calcitriol is essential for TPH2 gene activation in raphe neurons, which produces the serotonin that the SLC6A4 transporter then recycles; vitamin D deficiency impairs serotonin synthesis and supports depression susceptibility.
TNFSF11
Improves intestinal calcium absorption efficiency, reducing the need for RANKL (TNFSF11)-mediated bone resorption to maintain serum calcium; adequate vitamin D is the primary dietary intervention to reduce osteoclast-driven bone loss.
VDR
Vitamin D3 is the fundamental substrate required to produce active calcitriol, the direct ligand for VDR; supplementation efficacy depends on VDR expression level and genetic variants (Bsml, FokI, Taqt, ApaI) that alter receptor-mediated transcriptional activity.
Also mentioned in
ADRB2, AGT, ALK, APOE, APOL1, ATR, BCL2, BRCA1, C9orf72, CDH1, CTNNB1, CYP2C19, CYP2C9, CYP2D6, CYP3A4, DMD, EP300, ERBB2, ERCC1, FLT3, FOXO1, GDF11, IGF1, IL10, IL13, IL23R, JAK2, KL, KLF4, LRP5, MAPT, MDM2, MLH1, MYBPC3, NF1, NOD2, PALB2, PKD1, PKD2, POT1, PSEN1, PSEN2, PTPN22, RAD51, RET, RICTOR, SCN5A, SERPINA1, SERPINE1, SMAD4, SMN1, STAT3, TARDBP, TCF7L2, TERC, TERF2, TERT, TGFB1, TPO, TTN, CFTR
Safety & Dosing
Contraindications
Hypercalcemia or hypercalciuria: vitamin D supplementation is contraindicated as it will further increase calcium absorption and may worsen renal calcium deposition.
Granulomatous diseases (sarcoidosis, tuberculosis, lymphoma): these conditions involve extrarenal conversion of 25-OH-D to calcitriol by activated macrophages; supplementation can cause severe hypercalcemia.
Primary hyperparathyroidism: requires physician supervision as PTH-driven calcium dysregulation may be amplified.
Stage 4 to 5 chronic kidney disease: impaired renal 1-alpha hydroxylase activity means D3 supplementation may be less effective; patients often require active calcitriol (alfacalcidol) under physician guidance.
Drug Interactions
Thiazide diuretics: increase renal calcium reabsorption; combined with high-dose vitamin D can increase hypercalcemia risk
Corticosteroids: impair vitamin D metabolism and bone calcium utilization; higher vitamin D doses may be needed
Antiepileptics (phenytoin, carbamazepine): induce CYP enzymes that accelerate vitamin D catabolism; may require higher doses
Orlistat and bile acid sequestrants (cholestyramine): reduce fat-soluble vitamin absorption including vitamin D
Common Side Effects
At therapeutic doses (up to 4,000 IU/day), side effects are uncommon in individuals without underlying hypercalcemia risk
Toxicity symptoms at very high doses: nausea, vomiting, weakness, frequent urination, kidney stones, and soft tissue calcification; require monitoring of serum calcium and 25-OH-D
Studied Doses
600 to 800 IU per day is the RDA for adults; 1,000 to 2,000 IU per day for general sufficiency maintenance; 4,000 to 5,000 IU per day to correct deficiency; up to 10,000 IU per day considered safe for most adults based on toxicological review. Toxicity threshold in healthy adults is generally above 10,000 IU per day sustained for months. Target serum 25-OH-D: 40 to 60 ng/mL (100 to 150 nmol/L).
Mechanism of Action
VDR Nuclear Receptor Activation
Calcitriol (1,25-dihydroxyvitamin D3) binds VDR with subnanomolar affinity. The calcitriol-VDR complex heterodimerizes with the Retinoid X Receptor (RXR) and binds vitamin D response elements (DR3 VDREs) in gene promoters, recruiting SRC-1, p300/CBP, and other coactivators to drive transcription. Over 1,000 genes contain VDREs, spanning cell differentiation, immune regulation, calcium transport, and proliferation control.
RAAS Suppression and Cardiovascular Effects
Calcitriol directly represses the renin gene promoter, reducing angiotensin II production and RAAS-driven blood pressure elevation. This mechanism is supported by epidemiological data showing strong inverse correlations between 25-OH-D levels and hypertension prevalence. Calcitriol also supports vascular smooth muscle differentiation and endothelial function through VDR-mediated gene programs.
Immune Tolerance and Anti-inflammatory Signaling
Calcitriol shifts immune balance toward tolerance through multiple VDR-driven mechanisms: FOXP3 induction and Treg expansion, suppression of Th17 differentiation via RORγt reduction, IL-10 upregulation, and NF-κB inhibition through IκBα upregulation. Simultaneously, calcitriol enhances innate immunity by inducing cathelicidin (CAMP) and NOD2, explaining its paradoxical role in supporting both antimicrobial defense and immune tolerance.
Clinical Evidence
Vitamin D supplementation reduces fracture risk in meta-analyses of elderly populations (relative risk reduction approximately 20% for non-vertebral fractures with adequate doses). The VITAL trial showed a significant reduction in cancer mortality (24%) with 2,000 IU/day supplementation in a large US population. Observational evidence strongly links deficiency (25-OH-D below 20 ng/mL) with higher rates of autoimmune disease, infection, cardiovascular disease, and type 2 diabetes. Randomized trials in vitamin D-deficient populations show more consistent benefits than trials in replete populations, highlighting the importance of baseline status-guided supplementation rather than universal fixed-dose approaches.
Relevant Research Papers
Links go to PubMed (abstracts are public); some papers also offer free full text via PMC or the publisher.
Meta-analysis of RCTs demonstrating significant reductions in cancer mortality with vitamin D supplementation, with stronger effects in trials with adequate doses and longer follow-up durations, supporting the VDR-mediated anti-proliferative mechanisms.
Comprehensive review establishing the immunological mechanisms of calcitriol including Treg expansion, Th17 suppression, antimicrobial peptide induction, and NF-κB modulation, explaining the broad immune phenotypes associated with vitamin D deficiency.
Large cross-sectional study (NHANES data) demonstrating that serum 25-OH-D levels below 15 ng/mL are associated with significantly higher odds of hypertension, coronary artery disease, and diabetes, establishing the cardiovascular risk-vitamin D gradient.
Meta-analysis demonstrating that vitamin D3 supplementation significantly improves fasting blood glucose, HOMA-IR, and HbA1c in individuals with vitamin D deficiency, supporting calcitriol's role in pancreatic beta-cell function and insulin sensitivity.
Prospective cohort study showing that higher serum 25-OH-D levels at baseline were strongly associated with reduced risk of developing both type 1 and type 2 diabetes, providing longitudinal evidence for vitamin D's preventive role in metabolic and autoimmune diabetes.
Meta-analysis finding significant inverse association between 25-OH-D levels and depression; methodologically stronger studies showed effect sizes that were attenuated compared to earlier analyses, establishing a moderate but consistent relationship between vitamin D status and mood regulation.